Endemic and emerging acute virus infections in Indonesia: an overview of the past decade and implications for the future

Wesley de Jong, Musofa Rusli, Soerajja Bhoelan, Sofie Rohde, Fedik Rantam, Purwati Armand Noeryoto, Usman Hadi, Eric van Gorp, Marco Goeijenbier

Erasmus University Rotterdam

ABSTRACT

Being the largest archipelago country in the world, with a tropical climate and a unique flora and fauna, Indonesia habitats one of the most diverse biome in the world. These characteristics make Indonesia a popular travel destination, with tourism numbers increasing yearly. These characteristics also facilitate the transmission of zoonosis and provide ideal living and breading circumstances for arthropods, known vectors for viral diseases. A review of the past ten years of literature, reports of the Ministry of Health, Republic of Indonesia and ProMED-mail shows a significant increase in dengue infection incidence. Furthermore, chikungunya, Japanese encephalitis and rabies are proven to be endemic in Indonesia. The combination of cohort studies, governmental data and ProMED-mail reveals an integrated overview for those working in travel medicine and public health, focusing on both endemic and emerging acute virus infections. This review summarizes the epidemiology of acute virus infections in Indonesia, including outbreak reports, as well as public health response measurements and their potential or efficacy. Knowledge about human behavior, animal reservoirs, climate factors, environment and their role in emerging virus infection are discussed. We aim to support public health authorities and health care policy makers in a One Health approach.

INTRODUCTION

Comprising thousands of islands spread across the equator, Indonesia is the largest archipelago country in the world with 257.5 million inhabitants (1). With a broad offer of both culture and nature, Indonesia is a popular travel destination for travelers all over the world, with the number of travelers going to Indonesia increasing yearly (2). Traditionally, tourists visit both Java and Bali Island, but other islands such as Flores, Lombok, Sumatra and Sulawesi gain popularity, most likely due to effective advertisement of the islands. However, its tropical climate and subsequent relative high humidity are both favorable conditions for vector-borne disease transmission. In addition, Indonesia yields a large and growing population of notorious reservoirs of zoonotic infections like poultry, rodents, wild birds, dogs, pigs and monkeys (3-7).

This constant tread of infection and potential local outbreaks or even pandemics compromise both the people living in Indonesia as well as travelers visiting the archipelago. Infectious diseases remain one of the leading causes of morbidity and mortality worldwide, especially in countries with a (sub)tropical climate (8). Its burden is a result of a constant ground of established infections in the past period, combined with epidemics of emerging infectious diseases (EID) (9). An EID is characterized as an infectious disease that appeared and affected a population for the first time, or existed before but increased rapidly in case numbers or geographical spread. They often have the characteristic to easily spread over large areas, infecting people and/or animals with potential significant morbidity and mortality (10).

In the past decade, outbreaks of multiple emerging infectious virus diseases (EIVD) have been reported in Indonesia. Especially of note were those of avian influenza, dengue, chikungunya and rabies (4, 11-13). As a result, the Indonesian government has put much effort in trying to control many of these diseases, for instance by implementing surveillance and vector control programs, or in the case of rabies culling campaigns. This resulted in data of specific interest for those working with infectious disease patients in Indonesia, public health or those working in travel medicine outside of Indonesia. Data from local outbreak reports and from published epidemiological studies give a unique insight in how to optimize EIVD prevention in Indonesia. This data potentially can be used to support public health authorities and health care policy makers.

EI(V)D outbreaks are hard to predict since they are the result of a complex interaction between host, vector, pathogen and environment. Furthermore, infections in humans often happen unnoticed, such as via contaminated foods, mosquito bites or inhalation of virus containing aerosols. From the One Health concept we know that 6 out of every 10 infectious diseases in humans are spread from animals (14). An optimal insight in this interaction is crucial for executing adequate preventive methods, moreover since no treatment is available for the majority of acute EIVDs. A current overview of EIVDS in Indonesia for (international) clinicians and healthcare authorities does not seem to be available. Furthermore, we observed that authorities from other countries advising their inhabitants for pre-travel vaccinations and precautions could not adequately assess their advices since insight in local literature and governmental data for this region is lacking (Table 1).

Erasmus University Rotterdam

We therefore have reviewed acute (E)IVD outbreaks in Indonesia in the past decade, using published cohort data, ministry of health reports and reports from ProMED-mail; the online Program for Monitoring Emerging Diseases. ProMED-mail is open to all sources; it includes a variety of reports ranging from local media to science. Data should be interpreted with care, as reports are susceptible for information bias. Viral diseases able to unnoticeably transmit from vector to human or inter human are discussed as well. Table 2 summarizes the discussed viruses, incidence, transmission route, incubation period, symptomatology, protective actions and diagnostic methods.

Table 1. Vaccine preventable diseases as recommendation from the Ministry of Health Republic of Indonesia, Centers for Disease Control and Prevention, Dutch, Swiss, Singapore's and Australian perspective

Virus/Authority	MoH-RI (1)	CDC (2)	LCR (3)	Swiss TPH (4)	MoH-SG (5)	Australian Government (6)
Hepatitis A	No	All travellers	All travellers	All travellers	All travellers	All travellers
Hepatitis B	Yes	Tailored	Tailored *,**	Tailored *,***	Tailored	Tailored (not specified)
Japanese Encephalitis	No	Tailored †	Tailored ††	Tailored ††,†††	Tailored †	Tailored (not specified)
Measles	Yes	All travellers	All travellers	All travellers	All travellers	All travellers
Rabies	Tailored §§	Tailored §	Tailored §§	Tailored §§§	Tailored §	Tailored §

Footnotes

1) Ministry of Health, Republic of Indonesia, retrieved from: http://www.depkes.go.id
2) Center for Diseases Control and Prevention, Department of Health and Human Service, United States of America, retrieved from http://wwwnc.cdc.gov/travel/destinations/traveler/none/indonesia
3) Landelijk Coördinatiecentrum Reizigersadvisering (National Coordinationcentre for Traveladvise), the Netherlands, retrieved from https://www.mijnlcr.nl (professionals), http://www.lcr.nl (layman)
4) Swiss Tropical and Public Health Institute, Switzerland, retrieved from http://www.safetravel.ch (available in French and German only). Supplemented with data from Bundesambat für Gesundheit BAG, retrieved from http://www.bag.admin.ch/ekif/04423/04428/ (available in German only)
5) Ministry of Health, Republic of Singapore, retrieved from https://www.moh.gov.sg/ and https://www.healthhub.sg/ The latter refers to CDC (2) for vaccine advice
6) Australian Government, Department of Foreign Affairs and Trade, retrieved from http://smartraveller.gov.au/ No comprehensive travel immunization scheme could be found.
* For those having close contact with inhabitants, long-term stay or recreational activities with risk of injury (contaminated blood, non-sterile medical material)
** Implemented in national vaccination program since 2011 for all babies (ever since 1989 for specific populations such as newborns with a hepatitis B carrier mother)
*** Implemented in national vaccination program for all adolescents 11-15 years of age (vaccine status is checked at 25-29 years of age)
† For those spending ≥ 1 month in endemic areas during transmission season (including 1) long-term travelers, recurrent travelers, expatriates likely to visit rural/agriculture arease, 2) extensive outdoor (e.g. camping, farming), 3) staying in accomodation without air conditioning, screens or bed nets
†† For those spending ≥ 1 month on rural endemic area in close contact with ricefields and pig population.
††† During rainy season only
§ For those involved in outdoor activities, working with or around animals, taking long trips/moving into Indonesia, children
§§ For those with frequent and/or possible unnoticed exposure to domestic or wild mammals
§§§ For those with risk of high exposure (hikers, cyclists, cave explorers, zoologists) and those spending more than 3 months in country

Table 2. Overview of the major discussed viruses including epidemiology, symptomatology, protective actions and diagnostics Refer to full text for abbreviations. Refer to table 1. for vaccine recommendations and schedule. All of the information was taken from cdc.gov; incidence rates are referred to below.

Virus	Incidence*	Transmission via*	Incubation*	Symptomatology*	Protective actions*	Diagnostics
DENV	40:100.000 (MoH-RI, 2014)	Mosquito (*Aedes spp.*)	5-8 days	High fever accompanied with headache, retro-orbital, joint and/or muscle pain, rash, bleeding tendency	Avoid mosquito bites**	Acute phase: RT-PCR on plasma, antigen (NS1) based ELISA or rapid test. Convalescent: IgM/IgG antibodies***
WNV	No data available	Birds (reservoir), Mosquito (*Culex spp.*)	2-14 days	In 20% of cases a mild course: fever, headache, myalgia, rash and lymphadenopathy. <1% develops neurological symptoms.	Avoid mosquito bites**	Acute phase: RT-PCR on plasma or liquor, virus culture, immunohistochemistry on tissue. Convalescent: IgM/IgG antibodies on serum or liquor***
JEV	7.1:100.000 (children < 10yrs, Bali) (Kari et. al 2006)	Mosquito (*Culex spp.*)	6-16 days	In 1% fever, headache, altered mental state, convulsions (suspected meningitis, encephalitis or acute flaccid paralysis).	JEV vaccine, avoid, mosquito bites**	Acute phase: IgM antibodies on serum or liquor. Repeat on convalescent samples when high suspicion. Confirm with virus neutralization test. Convalescent: IgM/IgG antibodies ***
CHIKV	0,002 (MoH-RI, 2014) - 22 (MoH-RI, 2010) per 100.000	Mosquito (*Aedes spp.*)	2-4 days	Acute febrile illness, maculopapular rash and joint pain as key symptom.	Avoid mosquito bites**	Acute phase: RT-PCR on plasma, virus culture. Convalescent: IgM/IgG antibodies
MV	5 per 100.000 (MoH-RI, 2014)	Human-human (aerosols)	7-14 days	Fever, cough, coryza, conjunctivitis, Koplik's spots. Characteristic erythematous and maculopapular rash	Vaccination	Acute phase: RT-PCR on plasma and/or throat swab, urine. Convalescent: IgM/IgG antibodies (note: possible positive due to previous vaccination)
RABV	17 per 100.000 (MoH-RI, 2014)	Dogs, monkeys, bats bite/ scratch or licking damaged skin	As less as a few days	Flu like symptoms, progressive to cerebral dysfunction, agitation and eventual death when untreated	Vaccination (no need of immunoglobulins after bite/ scratch), avoid contact with animals. When indicated: adequate treatment with immunoglobulins (passive antibodies)	Test euthanized animal that possibly transmitted RABV (brain sample); concurrently test saliva (RT-PCR or virus isolation), serum, spinal fluid (antibodies) and skin biopsies in nape of the neck (antigen);

Refer to full text for abbreviations. Refer to table 1. for vaccine recommendations and schedule. All of the information was taken from cdc.gov; incidence rates are referred to below. (continued)

Virus	Incidence*	Transmission via*	Incubation*	Symptomatology*	Protective actions*	Diagnostics
HANV	No data available	Rodents (rats, mouse)	2-4 weeks (7 days was reported)	Flu like symptoms, high fever, bleeding tendency, kidney injury	Pest control, avoid contact with feces/urine of rodents (via food or by breathing in virus-containing particles)	Acute phase: RT-PCR. Convalescent: IgM/IgG and confirm with virus neutralization.
AI	No data available	Poultry	2-5 days	Conjunctivitis, influenza-like illness sometimes accompanied by gastro-intestinal symptoms and respiratory illness	Avoid contact with possible infected poultry. Preventively administer influenza antivirals.	RT-PCR on swab of upper respiratory tract (nose or throat).
HAV	No data available. Note: high seroprevalence (up to 100% in elderly).	With feces contaminated food, water, surfaces etc (fecal-oral).	15-50 days	Fever, fatigue, loss of appetite, gastro-intestinal symptoms, jaundice, dark urine. Below 6 years of age: 70% asymptomatic.	Vaccination	Acute: IgM on blood. Occasionally RT-PCR on blood or feces. Convalescent: IgM/IgG on blood
Influenza	No data available.	Human-human via droplets	1-4 days	Abrupt onset of respiratory signs and symptoms such as fever, myalgia, headache, malaise)	Yearly flu vaccine	When indicated: RT-PCR on swab of upper respiratory tract (nose or throat)

*   (n) refers to publication. Where MoH-RI is stated, information from Ministry of Health, Republic of Indonesia was used. Assumed population of 250x10^6.

**   to avoid mosquito bites: use insect repellent (such as DEET), wear proper clothing (long sleeves, pants etc) and reduce exposure to mosquitos during peak biting hours (i.e. for Aedes mosquito: early in morning and before dusk)

*** known cross-reactivity in flavivirus essays, interpret with care

METHODS

Based on manuscripts studying the epidemiology of virus infections in South East Asia and ProMED-mail reports, hepatitis A, West Nile virus, Japanese encephalitis, dengue, chikungunya, measles, rabies, hantavirus, avian influenza and seasonal influenza were considered to be predominantly associated with acute human viral disease in SEA region (15, 16). Since more recently, diseases such as Zika, hepatitis E and MERS-CoV (re-)emerged in the South-East Asia region; these were taken into consideration as well. We conducted a search of the literature for research performed in Indonesia and to human cases with a history of recent travel to Indonesia using the PubMed (including MesH) and Embase databases from May 12th to 19th, 2016**.** Search strategy is available as supplementary data (Supplementary data 1). Two authors independently selected articles written in English and Bahasa Indonesia by first reading title/abstract from human and animal/vector studies published from 2006 until May 2016. We checked reference lists for references to relevant first published data (i.e. first virus detection or clusters of cases) and we extracted data when available. Scientific literature about selected human research is available as supplementary data (Supplementary data 2). Figure 1 represents a map of Indonesia with a visual overview of the locations where the discussed cohort studies were conducted. We accessed Ministry of Health, Republic of Indonesia (MoH-RI) and World Health Organization (WHO) information at May 12th, 2016. MoH-RI reports for 2006-2015 were available for retrieval. Where applicable, WHO reports are referred to in text. Furthermore, ProMED-mail was searched for reports from Indonesia at Oct 21st, 2016. ProMED-mail together with MoH-RI data is visually presented in Figure 2 to give insight in the trends in reporting for some EIVDs of interest and is also available as supplementary data (Supplementary data 2).

Dengue virus (DENV)

Dengue virus (DENV) is a *Flavivirus* (genus including yellow fever and Zika virus) belonging to the family of *Flaviviridae*. DENV infection is a mosquito borne infection caused by one of the four DENV serotypes (DENV 1 to 4) and is primarily transmitted to humans by the *Aedes* mosquito. DENV has a worldwide distribution, is geographically concentrated around the equator and is endemic in Southeast Asia. The estimated number of infections worldwide is 50-100 million, with estimated 500.000 people requiring hospitalization each year. The incubation period is 5-8 days. Severe DENV could potentially lead to hemorrhagic shock and organ failure. Most of the symptoms become manifest around the time of defervescence. Treatment is supportive and mainly directed to maintenance of the body fluid volume. Safe and effective DENV vaccines are under development in several stages of research (17-22). Currently, Dengvaxia ® (a tetravalent, live attenuated, chimeric dengue vaccine in a yellow fever 17D backbone developed by Sanofi Pasteur) is registered for use in individuals 9-45 years of age living in endemic areas (23). However, current data does not support implementation in the Indonesian vaccination program.

Bali
Kari, 2006 (JEV)
Liu, 2010 (JEV)
Napoli, 2012 (DENV, CHIKV)
Susilawathi, 2012 (RABV)

Sumatera
Maha, 2009 (JEV)**
Perkasa, 2016 (ZIKA)

West Kalimantan
Maha, 2009 (JEV)**

Makassar
Sasmono, 2015 (DENV)

Papua
Maha, 2009 (JEV)**

Jakarta*
Konishi, 2009 (JEV)**
Soepandi, 2010 (AI)
Storms, 2015 (influenza)
Wertheim, 2015 (influenza)***

Bandung*
Porter, 2005 (DENV)
Kosasih, 2013 (CHIKV)
Kosasih, 2016 (DENV)

Surabaya*
Konishi, 2009 (JEV)**
Maha, 2009 (JEV)**
Yamakana, 2011 (DENV)
Mulyatno, 2012 (CHIKV)
Kotaki, 2014 (DENV)

Semarang* region
Suharti, 2009 (HANV)
Fahri, 2013 (DENV)

East/West Nusa Tenggara
Maha, 2009 (JEV)**

* City on Java island
** Multicenter study
*** Unspecified location

Figure 1. Map of Indonesia with location overview of the discussed cohort studies
Map of Indonesia with location overview of the discussed cohort studies conducted or reported from 2006 until May 2016 - not including case reports and/or export cases.

The nationwide DENV surveillance program started in 1968. Besides increasing DENV incidence numbers, surveillance showed an annual increase of dengue hemorrhagic fever (DHF), classified as DHF according to former classifications with at least two of four clinical manifestations (fever, hemorrhagic manifestations/positive tourniquet test, hepatomegaly and circulatory failure combined with thrombocytopenia) from 0.05/100000 to about 35-40/100000 in 2013. DHF incidence increased significantly in people aged 15 or above (11).

DENV import cases from Indonesia were reported in literature (24). For instance, in Norway 2 DENV infections were reported from 2008-2010 (25). Furthermore, in Italy (2010) an import case was reported with viremia lasting for several days. The authors stress out the importance of performing diagnostics and the potential for a local outbreak, since *Aedes* mosquitos are present in Italy (and other parts of Europe) (26).

There is data available suggesting a succeeding episode of DENV infection may lead to detrimental clinical disease, the so-called antibody depended enhancement theory. However, virulence seems mainly determined by difference in genotypes and increased virulence (17). Multiple studies report the continuous change of DENV serotypes and their lineages. Both clustering of lineages and subtypes during outbreaks (e.g. lineage 4 of DENV-2 between December 2011 and March 2012 (27-29)) as well as the concurrent presence of all four DENV genotypes is reported in Indonesia (29, 30).

Figure 2. Trends in ProMED-mail and Ministry of Health Republic of Indonesia for the reporting of chikungunya, rabies and avian influenza in Indonesia. Reporting up till 21st October 2016. Source data ProMED-mail available as supplementary data 2. Restricted to human cases (both laboratory confirmed and unconfirmed), not including summarizing outbreak reports. * indicates no data available.

Erasmus University Rotterdam

Clinical studies on the epidemiology of febrile illness in Indonesian cohorts report various rates of molecular, antigenic or serological evidence for DENV. Overall, for both urban and rural areas, DENV is detected in 12-55% of all tested febrile cases; this includes all four DENV genotypes. With a follow up period up to seven years in specific reports (31-34).

The MoH-RI national control program in the DENV epidemic includes surveillance of mosquito larvae in households and eradication of mosquito breeding spots, as a community-based program (35). The importance of such interventions is emphasized by several studies: Stahl *et al.* showed that indirect costs take up to 44% of the total costs (est. 2,979,902 US$) per DENV outbreak (36). Tourism and labor flow contributes to DENV incidence, as is shown in field research studies in Bali – one of the most popular islands as tourism destination. It is suggested to reduce vector populations and spread knowledge of vector transmittable diseases, though in this study no effect measurements are done (37).

To add up, multiple manuscripts suggest adjusting for underreporting DENV cases during an epidemic and to analyze current available data from cohort studies or MoH-RI with expansion factors (38, 39). Possible resistance to larvicides such as temephos (40), understanding the mosquito population (41) and the ability to predict the number of DENV cases in advance (42, 43) all could play an important role in further understanding of DENV outbreaks.

West Nile virus (WNV)

West Nile virus (WNV), an arthropod borne *Flavivirus*, is a zoonotic infection mainly of birds and horses. Birds serve as reservoir and transmission occurs via mosquitoes. WNV is found in West Asia, as well as Africa, Europe, Middle East and North America (44). Mammals are considered dead end hosts that do not contribute to the epidemic spread of the pathogen (45). The average incubation period lasts 2-14 days. Of humans infected, 20% will experience a mild, non-specific disease presentation including high fever, headache, myalgia, sometimes with rash and lymphadenopathy; <1% will develop severe neurological symptoms (46).

In Indonesia the data regarding WNV epidemiology is scarce. WNV was isolated from a 15-year-old patient with fever in 2004. Phylogenetic analysis showed a relation with WNV strains isolated in Africa (47). Only limited reports of WNV in humans in Indonesia are available. For instance based on the work of Nasronudin and Wicaksono *et al.* there is a suggestion of WNV infection in human in Indonesia (48, 49). However, these studies offer a low level of evidence since they used a sub-optimal methodology and confirmation by a third party lab was not performed. No surveillance program exists for WNV and no entries exist on ProMED-mail, thus only current case studies suggest potential circulation of WNV in Indonesia.

Japanese Encephalitis (JEV)

Japanese encephalitis virus (JEV) is an arthropod borne *Flavivirus*. It is the leading cause of encephalitis in most of South-East Asia and Western Pacific regions, where 24 countries are known to have endemic JEV transmission (50). The incubation period of JEV is 6-16 days. The majority

of cases are non-specific or asymptomatic; only less than 1% of the individuals develop clinical symptoms such as fever, headache, altered mental state and convulsions. When encephalitis occurs, mortality rises from 30% to 40-50 % in comatose patients. JEV is known for long-term neuropsychological sequelae in 30-50% of those who recover from intensive care support. Vaccination is considered the single and most important control measure for JEV (51, 52).

The first manuscript describing JEV in humans in Indonesia dates from 1974 (53). From then, a number of cases were reported in the 80-90s in both returning travelers (54-56) as well in Indonesian inhabitants (57). Early research to JEV was done on the reservoir (pigs) (58), vector (detected in both *Culex* and *Anophales* species)(58-60) and humans (53). Studies of *Yamakana et al.* investigated JEV viremia and antibodies in 219 pigs from Bali and East Java in 2008. Of these pigs 49% in Bali and 6% in Java had viremia and 24% of 123 pig samples tested in Bali showed positive JEV IgM antibodies (none in the Java population) (5). In contrast to the above-mentioned, only two human cases exist in ProMED-mail in 2011 and 2015, whereas sero-surveillance studies from 1999-2001 on Java Island detected 2.2% JEV antibodies (titers ≥ 1:160) involving over 2000 samples (6).

A number of clinical studies report a noteworthy incidence of JEV cases in children, of which a significant number report subsequent neurological sequelae. A study performed between 2001 and 2003, involving all healthcare facilities on Bali island, reported an average incidence rate of 7.1 per 100,000 children aged 10 or below (61). Another study followed up 65 out of 72 cases of laboratory confirmed JEV in children between 2001 and 2004. In this study, a total of 16 children were deceased at the follow-up assessment (average 13 months after discharge, range 4-24 months). No less than 25% of the children had sequelae in such way, that they were dependent in their daily functioning and only 25% of the children were considered to be fully recovered (62). A case-control study of Liu *et al.* confirmed JEV in about one third of the clinically identified viral encephalitis or aseptic meningitis in children aged 0-11 years. Multivariate analysis revealed that pig ownership by their family, close proximity to the rice fields and older age was significantly associated with the incidence risk of JEV in children (63). No such studies seem to have been carried out in adults in the past decade.

Despite being discussed at World Health Organization's meetings (64) and its relevance as pointed out above, currently no surveillance program nor a vaccination program exist in Indonesia, even while the latter was reported as cost-effective for a two-dose regime on Bali island (65). To our knowledge, the MoH-RI is advancing towards implementation of a childhood vaccine for JEV; it is however unclear what a surveillance program will look like.

Chikungunya (CHIKV)

Chikungunya virus (CHIKV) is an Alphavirus belonging to the *Togaviridae* family, transmitted in Asia by mosquitos of the *Aedes* family (66). After an incubation period of 2-4 days (range 1-12 days) (66, 67), the majority of the infected patients become symptomatic. CHIKV is characterized by an onset of acute febrile illness and maculopapular rash. Severe joint pain is described as main

Erasmus University Rotterdam

symptom and is present in almost all cases; arthralgia in specific cases can last up to 24 months (67, 68). Treatment is symptomatic. The re-emergence of CHIKV was reported in Indonesia in serological studies in 1999 (69) and in outbreak reports from 2001-2003 (70). Furthermore, CHIKV was isolated from patient sera in febrile illness cases from prospective cohorts from 2000-2008 – with incidence rates of 10.1/1000 CHIKV infections per person years (13, 71). When comparing MoH-RI reported incidence numbers of CHIKV in 2014 (72) to confirmed cases in a cohort study of 2010-2011, there is reason to believe that there is underreporting of CHIKV in Indonesia. This is likely the result due to the similarities in clinical presentation for both DENV and CHIKV (71), the sparse availability of routine diagnostics and not the trends in the CHIKV outbreak Figure 2 highlights these trends for CHIKV, avian influenza and rabies. Both MoH-RI and ProMED-mail data are prone to reporting bias; the figure shows clear trends and discrepancies in reporting between MoH-RI and ProMED-mail. For CHIKV, there seems a fixed ratio of ProMED-mail reports versus MoH-RI data in 2007 and 2008, whereas in later years it is definitely questionable how to adequately assess the real incidence numbers, since ProMED-mail numbers decline and MoH-RI numbers both drop and raise.

Measles (MV)

Measles virus (MV), a *Morbillivirus* belonging to the *Paramyxoviridae*, is a highly contagious virus, with the number of new infections that can result from one infected person ranging from 12-16 (also referred to in literature as the R_0). It spreads directly from human to human by virus containing aerosols. Especially at risk are people naïve to the virus, being those not vaccinated and children losing passive antibodies after birth. The infection is characterized by illness with fever, cough, coryza, conjunctivitis and Koplik's spots. A characteristic erythematous and maculopapular rash appears, which lasts for 3-5 days (73). In 40% of the cases measles infection is complicated, for instance by pneumonia, due to a relative immunosuppression after measles virus infection (74, 75). The incidence number of MV is successfully being reduced by vaccination, although outbreaks do occur, both in countries with and without vaccination program due to vaccine effectiveness and vaccine coverage (76, 77). The implementation of a regular immunization program for MV led to vaccination coverages above 90% in most of Indonesia, a target as set by WHO, with a declining number of provinces not meeting this target over the past years (78-80). When comparing these data to WHO reports, it can be depicted that the overall 1st dose coverage among 1-year olds is still below the 90% target (81). Also, ProMED-mail reports show no evidence of MV outbreaks, while MoH-RI still reports a number of cases totaling to an incidence rate of about 5-6 per 100.000 inhabitants (72, 80).

Rabies (RABV)

Rabies (RABV) is caused by a number of *Lyssaviruses* including the rabies virus and bat *Lyssaviruses*. Saliva from infected animals can transmit the virus to humans and eventually cause a lethal infection of the brains. In the majority of cases, dogs transmit the virus; however, transmission of

rabies via other wildlife should be taken into consideration (82). RABV causes an estimated number of deaths between fifty and a hundred thousand per year. The Asian and African continent account for 95% of the worldwide deaths of the total reported infections (83).

RABV is endemic in Indonesia, especially in Bali and East Nusa Tenggara and is likely present since the 1880s, based on multiple manuscripts describing clinical cases following bites from "mad dogs" (84). After being last described in late 1980s (85) an outbreak in Bali and surrounding islands commenced in 2008 (35). Up to hundred human cases and a case fatality rate of 100% in laboratory confirmed human cases were reported during the outbreak until 2010 (86). Of interest is the data from GeoSentinel and EuroTravNet sites; 12.1% of all post exposure prophylactic vaccination for RABV was requested by travelers returning form Bali. However, their data shows that the majority of animal-related injuries in travelers returning from Bali are associated with exposure to monkeys, and not dog bites/scratches (87). Figure 2 shows trends in RABV reporting to MoH-RI and ProMED-mail. The trends in reporting to both entities are less well correlated as compared to those in CHIKV. Figure 3 shows outbreak locations in Bali as reported in ProMED-mail and compared to MoH-RI incidence numbers. It could be beneficial to combine Ministry of Health, ProMED-mail and possibly WHO data to get a thorough overview of areas at risk in case of outbreaks, since locational data could be of relevance for governmental interventions or travel related risks.

To further understand the endemic, a number of animal studies were carried out. During the 2008-2010 outbreak *Dibia* and colleagues showed that Indonesian RABV originated from Java Island and were (re-)introduced in several other islands including Bali (88). Also, a study have been conducted to estimate the owned and unowned dog populations and dog bite cases in (RABV free) Lombok island (89) in order to get insight in the (potential) spread. From 2008, early preventive measurements to stop the outbreak were implemented. Despite control - including mass vaccinations and culling for dogs - the outbreak continued for four years. This largely had to do with the fact that the dog population in Bali is rather large and the human-dog relationship in Bali is believed to be multifaceted (i.e. for cultural reasons, as guard, but also different point-of-views in dog care and best practices after a bite wound) (90). Also culling of dogs seemed to be ineffective. The islands-wide vaccination, aiming for a vaccine coverage rate of 70% in dogs, did however reduce the incidence and spread of rabies (91). Still, a number of RABV cases are reported over the last years, as is summarized in Figures 2 and 3.

Hantavirus (HV)

Hantaviruses (HV) belong to the family of the *Bunyaviridae* . In humans, the rodent-borne HVs cause two different diseases. In North and South America inhalation of virus containing aerosols with new world hantaviruses could lead to the hantavirus cardio pulmonary syndrome , a syndrome characterized by fever and acute respiratory distress associated with high case fatality rates (92). Of importance for Indonesia, seem to be the so-called Old-World HVs which can cause hemorrhagic fever with renal syndrome (HFRS) (93). A triad of fever, hemorrhage and acute

Erasmus University Rotterdam

Figure 3. Rabies outbreak heat map to demonstrate the benefit of combining Ministry of Health and ProMED-mail data.

kidney injury classically characterizes this syndrome. It is crucial to initiate prompt and proper symptomatic and supportive treatment for HFRS. This includes monitoring of fluid balance, diuresis, kidney function and the use of fresh frozen plasma/transfusions in case of hemorrhagic complications (94). Small trials and case reports have shown that ribavirin treatment may be useful in the very early phase of HFRS by reducing the risk of hemorrhagic events and the severity of renal insufficiency. Larger trials are needed to corroborate these findings (95). In routine diagnostics, Old World HV infections are diagnosed by both serological detection of IgM and/or IgG antibodies and molecular detection of the virus. However, the extent of viremia varies per HV species and in some cases might be limited to a short period after onset of illness (92). Currently (comparative) virus neutralization tests remain the gold standard in HV serology to confirm an infection with a specific HV species. Neutralization tests remain an absolute necessity since current available serological HV diagnostics suffer from a high percentage of false positive results, and therefore reports solely relying on ELISA or IFA results should be interpret with care (96). Earlier studies suggested HV infection in humans and rodents in Indonesia (97-101) and a number of cases were found in hospital based cohort studies conducted between 1995 and 2005 (100, 102, 103). However, this evidence of human HV infection in Indonesia is based on only IgM ELISA proven cases. For instance, Suharti *et al.* report ELISA response of a recent infection in 4.2% of DENV suspected patients (103). Although not conclusive, this data does suggest symptomatic human HV infection in Indonesia, which is also supported by the results of Groen *et al.* who reported serological evidence, based on EIA, ELISA and IFA results in 11% in a DENV suspected cohort (102). Furthermore, serological evidence of HV infection was reported in a clustered case

of 2005 in Western Java (100). In this case, *rattus sp.* trapped around the living area of the patient showed the molecular presence of Seoul HV, known to cause HFRS in Europe. Seoul virus has been detected by PCR in *Rattus* norvegius, the known reservoir of the pathogenic Seoul virus (98) .

Furthermore, a newly discovered HV in the Thousand Island region in Indonesia, might be pathogenic to humans (101). Urgent studies are needed to estimate the burden of HV disease in humans in Indonesia and for adequate prevention methods (i.e. rodent trapping and human behavior changes).

Avian influenza (AI)

Avian influenza (AI) infection in human, caused by non-seasonal influenza A viruses of the subtypes H5N1 and H7N9 belonging to the *Orthomyxviridae* family, is clinically characterized by respiratory disease. The first AI H5N1 reported cases date from 1997 influenza in Hong Kong. Since then, the virus has spread throughout the South East of Asia with Indonesia being hit the hardest (104). In Indonesia, the epidemic in poultry started in December 2003 on Java Island, with now 31 out the 33 provinces being considered endemic. AI in humans was first detected in July 2005. Despite control measures to prevent further transmission among poultry, the infection rate among humans declined from 5 to 3 cases per month in the reports of 2008 (105). Up to 2015, a total of 195 cases have been WHO confirmed in Indonesia, of which 165 were fatal - mainly in the period of 2005-2009 (104). Reports over 2014 show a continuation of the decline and only 2 cases are reported in the archipelago (72). Refer to Figure 2 for an overview of MoH-RI reports and trends in ProMED-mail reporting of AI. The importance of early ProMED-mail reports is clearly shown here, as the number of reports constantly seems to exceed MoH-RI data, which could indicate impaired implementation of a governmental program (underreporting to the government). Unfortunately, one cannot rule out (unverifiable) over reporting in ProMED-mail.

Transmission of the disease considered to be caused by direct exposure to infected poultry. Several family case clusters (106) have been reported suggesting the possibility of human-to-human transmission in a study of Yang *et al.* (107). However, transmission estimates were only based on one cluster. In addition, blood relatives were shown to be at risk of infection in household outbreaks, supporting the hypothesis for genetic host susceptibility (108, 109). Recent data showed that only a couple mutations in current circulating highly pathogenic AI H5N1 viruses, would be enough to enhance human-to-human airborne transmission (110). This illustrates the pandemic potential and possible concerns for international public health.

Several measures have been taken to control disease, comprising vaccination of poultry and implementation of a participatory disease surveillance (PDS) program, a community-based reporting system (111, 112). At the beginning of the outbreaks, control of disease has been problematic due to poor gathering of epidemiological information. Since the start of PDS, registration of new cases has been greatly enhanced. Taking social and cultural context of dynamics and distribution of disease into account has been valuable in this process (111).

Erasmus University Rotterdam

Hepatitis A (HAV)

Indonesia was generally considered to be part of the Hepatitis A (HAV) endemic regions of the world. This food-borne infection with HAV, related to decreased sanitation conditions, infects over 90% of children under the age of 10 years in endemic regions (113). Since the infection before the age of five is rather asymptomatic, the burden of disease for inhabitants in endemic regions is rather low, resulting in a high level of community based immunity for acute HAV infections. Therefore, hardly any outbreaks occur within the community. In upcoming economies like Indonesia, however, the number of infected children drops with a subsequent increase in symptomatic infections on an older age as a results of a clear increase in level of sanitation (114). This decline in seroprevalence amongst children and adolescents has been reported in Indonesia and other countries on the continent (115). This change in epidemiologic pattern has clinical and public health implications, where at some point the introduction of nation-wide HAV vaccination might be cost effective compared to treatment of acute HAV infection (116), which is symptom driven. For persons travelling to Indonesia, HAV vaccination is generally recommended by travel medicine guidelines (refer to Table 1) - especially for adults, and imported cases of HAV from travelers to and from Indonesia have been broadly reported in literature (117, 118).

Seasonal influenza and influenza like ilnesses

Influenza viruses, the most well-known members of *Orthomyxoviridae* family, cause respiratory disease in humans predominantly. Those mimicking the symptoms of Influenza are known as non-influenza viruses, causing influenza like illnesses. Of the three influenza virus types (A, B and C), influenza A is the best known for its ability to drift, re-assort and the cause of seasonal human flu on a yearly base. Influenza A affects 5-15% of the human population every year. In the tropical Indonesia climate, no true seasonality of influenza is present (119). The virus seems to be constantly present and cause respiratory disease throughout the whole year. However, Storms *et al*. studied the prevalence of influenza virus in patients seeking care for respiratory disease in Jakarta, Java over a one-year period starting in 2011 and reported the highest incidence during December-May with the proportion of positive PCR being 76% for patients presenting with classic influenza like illness. Of those, 36% had more severe disease during the weeks with highest influenza activity (120). Most likely, seasonality exists in line with rainy season. Currently, no country-based policies regarding influenza vaccination (such as for risk groups, healthcare professionals etc) are implemented in Indonesia.

MoH-RI discusses the recommendation of antivirals like oseltamivir or vaccination policies in Indonesia, since several studies report this high percentage of complicated influenza cases in Indonesia (up to 15%), (120-122). Of interest for clinicians dealing with travelers with travel plans to Indonesia, comes from data of the Geosentinel network. It shows that travelers travelling to South East Asia have a sevenfold higher change of being infected with seasonal influenza compared to those staying at home (123). It therefore seems reasonable to vaccinate travelers and

inhabitants; however, a yearly seasonal influenza vaccine is currently not implemented in any Indonesian immunization schedule (Table 1) (124).

During a one-year study from 2008, just above 200 respiratory specimens from patients hospitalized in Indonesia (total 1222 patients including hospitals in Thailand and Vietnam) with suspected influenza or influenza like illness were collected and analyzed. In the cohort, 18.7% of the samples tested positive for Rhinovirus, in particular in March. Furthermore, respiratory syncytial virus (RSV, 11.8%) was found from July to November. Other detected viruses included bocavirus (16.4%), parainfluenza (11.5%), adenovirus (8.4%), influenza A and B (7.6%) and coronaviruses (1.8%) (125).

Zika virus infection, hepatitis E, MERS Corona

Three cases of Zika virus infection, caused by a *Flavivirus* transmitted by *Aedes aegypti* mosquitos, in Indonesia are reported in literature. These infections, clinically characterized by fever, headache, malaise, arthralgia, myalgia and rash, were all documented in returning travelers from Jakarta (2012, after 9 day holiday)(126), Bali (2013, after monkey bite in Ubud Monkey Forest) (127) and Malaysian Borneo (2014, after a 3 week holiday)(128).

Also seven cases of probable Zika virus infection in inpatient inhabitants of Central Java were reported based on antibody diagnostics (129). In samples collected in 2014-2015, during a DENV outbreak in Jambi (n=103), one DENV negative sample was tested positive for Zika (130). Once, a monkey bite was proposed as a route of transmission, while Zika is generally considered to be a mosquito-borne disease (127). Since both DENV and Zika manifest clinically similar, it remains unclear whether Zika virus infection is rare in Indonesia or is often mistaken for DENV. Only limited, if none, diagnostics are carried out to Zika and no regular surveillance programs exist (72).

Three outbreaks of hepatitis E infections, transmitted fecal-orally and associated with low standards of sanitation, have been described in West-Kalimantan and Java (131-133). All three outbreaks were related to dependence to polluted river water. Anti-hepatitis E virus seropositivity is shown to be more prevalent in regions where pigs and swines are more incorporated in daily life, as is the case in Bali island, compared to Java. Samples were taken from farms in Yogjakarta (Central Java), Tulungagung (East Java) and Mengwi (Bali) (134, 135). Also hepatitis E virus has been detected in wild rats, however whether their role in human infection is significant or not remains unclear (136).

Middle East respiratory syndrome corona virus (MERS-CoV) causes upper respiratory infections in humans with case fatality rates up to 35%. MERS-CoV is prevalent in Arabian countries, including Saudi-Arabia, which is visited by Indonesian inhabitants for hajj (pilgrimage) (137). So far, no cases of MERS corona virus infections in Indonesia are reported in literature.

Implications and future actions

Summarized data from scientific literature, WHO reports, reports from the Ministry of Health of the Republic of Indonesia and ProMED-mail, presented in this review, provide a unique insight in

Erasmus University Rotterdam

the past, current and potential of relevant viral pathogens for the Indonesian archipelago. Indonesia seems to be prone to vector-borne and zoonotic diseases, due to environmental conditions suited for arthropod vectors and the presence of reservoirs for zoonotic viruses. Viruses like DENV have been endemic for many years while re-emergence of AI and RABV have drawn attention from governmental institutes and scientists. Relevant for this region, but underreported in MoH reports and literature are HV, HAV and JEV. Furthermore, only limited data is available about the incidence of influenza and influenza like illnesses – while these viruses are known to have a significant burden on society in due to economical losses. Furthermore, these viruses most likely account for a substantial number of hospital admissions for the very young or elderly, as they do in Europe and U.S.A.

The description of a (re-)emerging virus is expected to happen in the order of ProMED-mail reports, scientific studies and governmental data (MoH-RI and CDC or WHO). Only parts of the ProMED-mail data regarding outbreak reports were confirmed or became of scientific interest in cohort studies (i.e. this holds especially true for avian influenza). Ministry of Health (MoH-RI) data seems to be partially in line with these findings. ProMED-mail has proven to be a valuable tool in the (early) detection of outbreaks all over the world. For Indonesia, this is very well illustrated with AI reports, for which, in many cases, the ProMED-mail reports are ahead of official statements and literature. Interestingly, ProMED-mail reporting for the rabies outbreak in Bali started in 2010 (Figure 2), while most likely the outbreak started in 2008. Given the goal of ProMED-mail to report emerging diseases on a low-threshold base, it relies heavily on the awareness and possibilities to report (unknown) cases by local healthcare workers. This shows the importance for adequate on-site diagnostics and surveillance programs. To our experience, the rabies under reporting seems to be an exception in ProMED-mail.

We noticed some discrepancies in MoH-RI data as compared to WHO and CDC data. In MoH-RI data it is not always clear whether data was not available (i.e. not reported to the government) or no cases occurred at all. Furthermore, limited insight is given in number of suspected cases versus laboratory confirmed cases. In case of RABV, the number of suspected cases (as measured by the number of animal bites) versus administration of RABV vaccine and number of *confirmed* and fatal cases is reported. Information about the used diagnostic methods lacks, as well as the number of tested samples versus laboratory confirmed samples. Since data is not available for local persons exposed to RABV, it is impossible to draw conclusions based on these observations. However, we do know, with special focus on Bali Island, that RABV post exposure is the number two most prevalent post travel health care problem in travelers as per Geosentinal data - just above influenza and below travelers' diarrhea. The number of actual RABV cases, luckily, is actually one of the more rare problems. We also observed over reporting in ProMED-mail, as only few reports of DENV in ProMED-mail exist but dozens of reports for CHIKV and AI were added; we were unable to settle this discrepancy, moreover since both are reported to the government and taken to MoH-RI reports over the past years. ProMED-mail entries should be interpreted with care, as its form is prone to reporting bias and no peer-review system exists.

There is a clear unmet need for cohort studies in a number of primary, secondary and tertiary care centers evenly spread over the archipelago. In particular, some well-studied acute viral diseases such as influenza and influenza like illnesses are only limitedly researched in Indonesia. Furthermore, up-to-date scientific information regarding for instance HAV and MV antibody prevalence – and hence – the risk for those unvaccinated seems to lack for this region.

Incidence numbers as reported in scientific studies serve a different purpose than those reported in MoH-RI (or CDC, WHO) data, due to the selection of a specific population (i.e. a poultry market, hospital based or clinical symptoms). These data should guide healthcare workers in their decisions when assessing patients in the general practice or emergency department. Healthcare workers should therefore be able to rely on solid surveillance data from the MoH-RI as well as scientific literature.

In recent years, CHIKV (2013, Caribbean islands), Ebola (2014, West Africa) and Zika (2015, South America and 2016, Asia), have proved to be of relevance for both developed and developing countries. No exception exists for Indonesia, especially since Indonesia is an upcoming economy and a popular travel destination. Vector control is relevant in order to control outbreaks. The MoH-RI sets targets to lower the number of larvae around houses as well as targets for lowering the incidence rate for new cases (e.g. DENV) on a yearly base. Next to this challenging task, there is need for a functional and validated surveillance program. Government reference laboratories are only available in limited numbers and the geographic layout in terms of the archipelago, including distant areas and a variety in both economic strength and availability of health care facilities, poses another challenge to get an accurate oversight EIVD epidemiology.

Changes to the Indonesian vaccination program will be needed to be made in the future, as new vaccines and epidemiological data become available. This especially holds true for new DENV vaccines and existing JEV (refer to Table 1, comparing the MoH-RI immunization scheme to travel immunization advice). Preparedness for EI(V)Ds can only be achieved with an adequate insight and control of current pathogens, a solid surveillance system including reference laboratories and the ability to scale up the resources needed to adequately diagnose, treat and follow-up patients. To our findings, resources should be directed to the One Health concept as it is of utmost importance to achieve the correct balance for people, animals and the environment. Given recent outbreaks in the world, the existence of vectors in Indonesia and the ability to spread diseases in humans, poultry or goods, it might just be a matter of time before other well-known viral diseases such as yellow fever, or other emerging diseases will be engrafted in Indonesia.

Supplementary data 1, 2 and 3 are available from: https://doi.org/10.1080/104084 1X.2018.1438986

REFERENCES

1. Worldbank Indonesia Data 2016 [Available from: http://data.worldbank.org/country/indonesia

2. Forum.; WE. Travel and Tourism Competitiveness Report: World Economic Forum; World Economic Forum 2015 [Available from: http://reports.weforum.org/travel-and-tourism-competitiveness-report-2015/economies/#economy=IDN.

3. Lane-DeGraaf KE, Putra IG, Wandia IN, Rompis A, Hollocher H, Fuentes A. Human behavior and opportunities for parasite transmission in communities surrounding long-tailed macaque populations in Bali, Indonesia. Am J Primatol. 2014;76(2):159-67.

4. Townsend SE, Sumantra IP, Pudjiatmoko, Bagus GN, Brum E, Cleaveland S, et al. Designing programs for eliminating canine rabies from islands: Bali, Indonesia as a case study. PLoS Negl Trop Dis. 2013;7(8):e2372.

5. Yamanaka A, Mulyatno KC, Susilowati H, Hendrianto E, Utsumi T, Amin M, et al. Prevalence of antibodies to Japanese encephalitis virus among pigs in Bali and East Java, Indonesia, 2008. Jpn J Infect Dis. 2010;63(1):58-60.

6. Konishi E, Sakai Y, Kitai Y, Yamanaka A. Prevalence of Antibodies to Japanese Encephalitis Virus among Inhabitants in Java Island, Indonesia, with a Small Pig Population. Am J Trop Med Hyg. 2009;80(5):856-61.

7. Dash AP, Bhatia R, Sunyoto T, Mourya DT. Emerging and re-emerging arboviral diseases in Southeast Asia. J Vector Borne Dis. 2013;50:77-84.

8. WHO. The top 10 causes of death: WHO; 2014 [updated May 2014. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/.

9. Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. Nature. 2004;430(6996):242-9.

10. WHO-SEARO. Combating emerging infectious diseases in the South-East Asia Region. New Delhi: World Health Organization Regional Office for South-East Asia (WHO-SEARO); 2005.

11. Karyanti MR, Uiterwaal CS, Kusriastuti R, Hadinegoro SR, Rovers MM, Heesterbeek H, et al. The changing incidence of Dengue Haemorrhagic Fever in Indonesia: a 45-year registry-based analysis. BMC Infectious Diseases. 2014;14(412).

12. Soepandi PZ, Burhan E, Mangunnegoro H, Nawas A, Aditama TY, Partakusuma L, et al. Clinical course of avian influenza A(H5N1) in patients at the Persahabatan Hospital, Jakarta, Indonesia, 2005-2008. Chest. 2010;138(3):665-73.

13. Kosasih H, de Mast Q, Widjaja S, Sudjana P, Antonjaya U, Ma'roef C, et al. Evidence for endemic chikungunya virus infections in Bandung, Indonesia. PLoS Negl Trop Dis. 2013;7(10):e2483.

14. CDC. One Health: Centers for Disease Control and Prevention; 2016 [updated November 2, 2016. Available from: https://www.cdc.gov/onehealth/.

15. Cleton N, Koopmans M, Reimerink J, Godeke GJ, Reusken C. Come fly with me: review of clinically important arboviruses for global travelers. J Clin Virol. 2012;55(3):191-203.

16. WHO. A brief guide to emerging infectious diseases and zoonoses: World Health Organization Regional Office for South-East Asia; 2014 [updated 2014. Available from: http://www.searo.who.int/entity/emerging_diseases/ebola/a_brief_guide_emerging_infectious_diseases.pdf.

17. Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev. 2009;22(4):564-81.

18. Meltzer E, Schwartz E. A travel medicine view of dengue and dengue hemorrhagic fever. Travel Med Infect Dis. 2009;7(5):278-83.

19. Ooi EE, Gubler DJ. Dengue in Southeast Asia: epidemiological characteristics and strategic challenges in disease prevention. Cad Saude Publica. 2009;25 Suppl 1:S115-24.

20. Mangold KA, Reynolds SL. A review of dengue fever: a resurging tropical disease. Pediatr Emerg Care. 2013;29(5):665-9; quiz 70-1.

21. Vannice KS, Durbin A, Hombach J. Status of vaccine research and development of vaccines for dengue. Vaccine. 2016;34(26):2934-8.

22. Chen LH, Wilson ME. Dengue and chikungunya infections in travelers. Curr Opin Infect Dis. 2010;23(5):438-44.

23. WHO. Immunization, Vaccines and Biologicals Dengue vaccine research: WHO; 2016 [updated 29-07-2016. Available from: http://www.who.int/immunization/research/development/dengue_vaccines/en/

24. Napoli C, Salcuni P, Pompa MG, Declich S, Rizzo C. Estimated imported infections of Chikungunya and Dengue in Italy, 2008 to 2011. J Travel Med. 2012;19(5):294-7.

25. Vainio K, Noraas S, Holmberg M, Fremstad H, Wahlstrom M, Anestad G, et al. Fatal and mild primary dengue virus infections imported to Norway from Africa and south-east Asia, 2008-2010. Euro Surveill. 2010;15(38).

26. Rovida F, Percivalle E, Campanini G, Piralla A, Novati S, Muscatello A, et al. Viremic Dengue virus infections in travellers: potential for local outbreak in Northern Italy. J Clin Virol. 2011;50(1):76-9.

27. Ernst T, McCarthy S, Chidlow G, Luang-Suarkia D, Holmes EC, Smith DW, et al. Emergence of a new lineage of dengue virus type 2 identified in travelers entering Western Australia from Indonesia, 2010-2012. PLoS Negl Trop Dis. 2015;9(1):e0003442.

28. Yamanaka A, Mulyatno KC, Susilowati H, Hendrianto E, Ginting AP, Sary DD, et al. Displacement of the predominant dengue virus from type 2 to type 1 with a subsequent genotype shift from IV to I in Surabaya, Indonesia 2008-2010. PLoS One. 2011;6(11):e27322.

29. Kotaki T, Yamanaka A, Mulyatno KC, Labiqah A, Sucipto TH, Churrotin S, et al. Phylogenetic analysis of dengue virus type 3 strains primarily isolated in 2013 from Surabaya, Indonesia. Jpn J Infect Dis. 2014;67(3):227-9.

30. Kotaki T, Yamanaka A, Mulyatno KC, Churrotin S, Labiqah A, Sucipto TH, et al. Continuous dengue type 1 virus genotype shifts followed by co-circulation, clade shifts and subsequent disappearance in Surabaya, Indonesia, 2008-2013. Infect Genet Evol. 2014;28:48-54.

31. Fahri S, Yohan B, Trimarsanto H, Sayono S, Hadisaputro S, Dharmana E, et al. Molecular surveillance of dengue in Semarang, Indonesia revealed the circulation of an old genotype of dengue virus serotype-1. PLoS Negl Trop Dis. 2013;7(8):e2354.

32. Porter KR, Beckett CG, Kosasih H, Tan RI, Alisjahbana B, Rudiman PI, et al. Epidemiology of dengue and dengue hemorrhagic fever in a cohort of adults living in Bandung, West Java, Indonesia. Am J Trop Med Hyg. 2005;72(1):60-6.

33. Sasmono RT, Wahid I, Trimarsanto H, Yohan B, Wahyuni S, Hertanto M, et al. Genomic analysis and growth characteristic of dengue viruses from Makassar, Indonesia. Infect Genet Evol. 2015;32:165-77.

34. Kosasih H, Alisjahbana B, Nurhayati, de Mast Q, Rudiman IF, Widjaja S, et al. The Epidemiology, Virology and Clinical Findings of Dengue Virus Infections in a Cohort of Indonesian Adults in Western Java. PLoS Negl Trop Dis. 2016;10(2):e0004390.

35. MoH-RI. [Indonesia Health Profile 2008] Jakarta: Ministry of Health - Republic of Indonesia (MoH-RI) [in Indonesian]; 2009 [Available from: http://www.depkes.go.id/folder/view/01/structure-publikasi-pusdatin-profil-kesehatan.html.

36. Stahl HC, Butenschoen VM, Tran HT, Gozzer E, Skewes R, Mahendradhata Y, et al. Cost of dengue outbreaks: literature review and country case studies. BMC Public Health. 2013;13:1048.

Erasmus University Rotterdam

37. Yoshikawa MJ, Kusriastuti R. Surge of dengue virus infection and chikungunya Fever in bali in 2010: the burden of mosquito-borne infectious diseases in a tourist destination. Trop Med Health. 2013;41(2):67-78.

38. Undurraga EA, Halasa YA, Shepard DS. Use of expansion factors to estimate the burden of dengue in Southeast Asia: a systematic analysis. PLoS Negl Trop Dis. 2013;7(2):e2056.

39. Shepard DS, Undurraga EA, Halasa YA. Economic and disease burden of dengue in Southeast Asia. PLoS Negl Trop Dis. 2013;7(2):e2055.

40. Mulyanto KC, A. Y, Ngadino, Konishi E. Resistance of Aedes aegypti (L.) larvae to temephos in Surabaya, Indonesia. Southeast Asian J Trop Med Public Health. 2012;43(1):29-33.

41. Rasic G, Endersby-Harshman N, Tantowijoyo W, Goundar A, White V, Yang Q, et al. Aedes aegypti has spatially structured and seasonally stable populations in Yogyakarta, Indonesia. Parasit Vectors. 2015;8:610.

42. Halide H, Ridd P. A predictive model for Dengue Hemorrhagic Fever epidemics. Int J Environ Health Res. 2008;18(4):253-65.

43. Wijayanti SP, Sunaryo S, Suprihatin S, McFarlane M, Rainey SM, Dietrich I, et al. Dengue in Java, Indonesia: Relevance of Mosquito Indices as Risk Predictors. PLoS Negl Trop Dis. 2016;10(3):e0004500.

44. Chancey C, Grinev A, Volkova E, Rios M. The global ecology and epidemiology of West Nile virus. Biomed Res Int. 2015;2015:376230.

45. van der Meulen KM, Pensaert MB, Nauwynck HJ. West Nile virus in the vertebrate world. Arch Virol. 2005;150(4):637-57.

46. Watson, Pertel PE, Jones RC, Siston AM, Paul WS, Austin CC, et al. Clinical characteristics and functional outcomes of West Nile Fever. Ann Intern Med. 2004;141(5):360-5.

47. Myint KS, Kosasih H, Artika IM, Perkasa A, Puspita M, Ma'roef CN, et al. West Nile virus documented in Indonesia from acute febrile illness specimens. Am J Trop Med Hyg. 2014;90(2):260-2.

48. Nasronudin, Aksono B, Lukito B, Rachman B, Noordiansyah, Indrawati R, et al., editors. West nile Virus (WNV) as a potential new threat to HIV/ AIDS patients in Indonesia. 32nd World Congress of Internal Medicine (WCIM); 2014 October 28,; Seoul. Seoul: Korean Association of Internal Medicine.

49. Wicaksono E, Soekarman B, Hadi U, editors. A patient with acute disseminated encephalopathy caused by West Nile infection. 32nd World Congress of Internal Medicine (WCIM); 2014 October 28,; Seoul. Seoul: Korean Association of Internal Medicine.

50. WHO. Japanese encephalitis: WHO; 2015 [updated December 2015. Available from: http://www.who.int/mediacentre/factsheets/fs386/en/.

51. Unni SK, Ruzek D, Chhatbar C, Mishra R, Johri MK, Singh SK. Japanese encephalitis virus: from genome to infectome. Microbes Infect. 2011;13(4):312-21.

52. Tiwari S, Singh RK, Tiwari R, Dhole TN. Japanese encephalitis: a review of the Indian perspective. Braz J Infect Dis. 2012;16(6):564-73.

53. Van Peenen PF, Anderson KE, See R, Nasution R. Serological evidence of arbovirus infection in febrile hospitalized patients in Jakarta, Indonesia during 1970-71. J Trop Med Hyg. 1974;77(10):244-6.

54. Macdonald WB, Tink AR, Ouvrier RA, Menser MA, de Silva LM, Naim H, et al. Japanese encephalitis after a two-week holiday in Bali. Med J Aust. 1989;150(6):334-6, 9.

55. Wittesjo B, Eitrem R, Niklasson B, Vene S, Mangiafico JA. Japanese encephalitis after a 10-day holiday in Bali. Lancet. 1995;345(8953):856-7.

56. Buhl MR, Black FT, Andersen PL, Laursen A. Fatal Japanese encephalitis in a Danish tourist visiting Bali for 12 days. Scand J Infect Dis. 1996;28(2):189.

57. Yoshida M, Igarashi A, Suwendra P, Inada K, Maha MS, Kari K, et al. The first report on human cases serologically diagnosed as Japanese encephalitis in Indonesia. Southeast Asian J Trop Med Public Health. 1999;30(4):698-706.

58. Van Peenen PF, Joseph PL, Atmosoedjono S, Irsiana R, Saroso JS. Japanese encephalitis virus from pigs and mosquitoes in Jakarta, Indonesia. Trans R Soc Trop Med Hyg. 1975;69(5-6):477-9.

59. Olson JG, Ksiazek TG, Lee VH, Tan R, Shope RE. Isolation of Japanese encephalitis virus from Anopheles annularis and Anopheles vagus in Lombok, Indonesia. Trans R Soc Trop Med Hyg. 1985;79(6):845-7.

60. Olson JG, Ksiazek TG, Tan R, Atmosoedjono S, Lee VH, Converse JD. Correlation of population indices of female Culex tritaeniorhynchus with Japanese encephalitis viral activity in Kapuk, Indonesia. Southeast Asian J Trop Med Public Health. 1985;16(2):337-42.

61. Kari K, Liu W, Gautama K, Mammen MP, Jr., Clemens JD, Nisalak A, et al. A hospital-based surveillance for Japanese encephalitis in Bali, Indonesia. BMC Med. 2006;4:8.

62. Maha MS, Moniaga VA, Hills SL, Widjaya A, Sasmito A, Hariati R, et al. Outcome and extent of disability following Japanese encephalitis in Indonesian children. Int J Infect Dis. 2009;13(6):e389-93.

63. Liu W, Gibbons RV, Kari K, Clemens JD, Nisalak A, Marks F, et al. Risk factors for Japanese encephalitis: a case-control study. Epidemiol Infect. 2010;138(9):1292-7.

64. Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine. 2000;18 Suppl 2:1-25.

65. Liu W, Clemens JD, Kari K, Xu ZY. Cost-effectiveness of Japanese encephalitis (JE) immunization in Bali, Indonesia. Vaccine. 2008;26(35):4456-60.

66. Caglioti C, Lalle E, Castilletti C, Carletti F, Capobianchi MR, Bordi L. Chikungunya virus infection: an overview. New Microbiol. 2013;36(3):211-27.

67. Thiberville SD, Moyen N, Dupuis-Maguiraga L, Nougairede A, Gould EA, Roques P, et al. Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy. Antiviral Res. 2013;99(3):345-70.

68. Kucharz EJ, Cebula-Byrska I. Chikungunya fever. Eur J Intern Med. 2012;23(4):325-9.

69. Porter KR, Tan R, Istary Y, Suharyono W, Sutaryo, Widjaja S, et al. A serological study of Chikungunya virus transmission in Yogyakarta, Indonesia: evidence for the first outbreak since 1982. Southeast Asian J Trop Med Public Health. 2004;32(2):408-15.

70. Laras K, Sukri NC, Larasati RP, Bangs MJ, Kosim R, Djauzi, et al. Tracking the re-emergence of epidemic chikungunya virus in Indonesia. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2005;99(2):128-41.

71. Mulyatno KC, Susilowati H, Yamanaka A, Soegijanto S, Konishi E. Primary isolation and phylogenetic studies of Chikungunya virus from Surabaya, Indonesia. Jpn J Infect Dis. 2012;65:92-4.

72. MoH-RI. [Indonesia Health Profile 2014] Jakarta: Ministry of Health - Republic of Indonesia (MoH-RI) [in Indonesian]; 2015 [Available from: http://www.depkes.go.id/folder/view/01/structure-publikasi-pusdatin-profil-kesehatan.html.

73. Moss WJ, Griffin DE. Measles. Lancet. 2012;379(9811):153-64.

74. de Vries RD, McQuaid S, van Amerongen G, Yuksel S, Verburgh RJ, Osterhaus AD, et al. Measles immune suppression: lessons from the macaque model. PLoS Pathog. 2012;8(8):e1002885.

75. Mina MJ, Metcalf CJ, de Swart RL, Osterhaus AD, Grenfell BT. Long-term measles-induced immuno-modulation increases overall childhood infectious disease mortality. Science. 2015;348(6235):694-9.

76. Durrheim DN, Crowcroft NS, Strebel PM. Measles - The epidemiology of elimination. Vaccine. 2014;32(51):6880-3.

77. WHO. Global measles and rubella strategic plan : 2012-2020. Geneve: World Health Organization; 2012.

78. Serquina-Ramiro L, Kasniyah N, Inthusoma T, Higginbotham N, Streiner D, Nichter M, et al. Measles immunization acceptance in Southeast Asia: past patterns and future challenges. Southeast Asian J Trop Med Public Health. 2001;32(4):791-804.

79. Dalimunthe S, Tjipta GD, Lubis IZ, Manoeroeng SM, Lubis CP. Immunization in the Well Baby Clinic of Dr. Pirngadi Hospital Medan. Paediatr Indones. 1990;30(1-2):42-53.

80. MoH-RI. [Indonesia Health Profile 2013] Jakarta: Ministry of Health - Republic of Indonesia (MoH-RI) [in Indonesian]; 2014 [Available from: http://www.depkes.go.id/folder/view/01/structure-publikasi-pusdatin-profil-kesehatan.html.

81. WHO. Immunization surveillance, assessment and monitoring (Measles 1st dose (MCV1) immunization coverage among 1-year olds, 1980-2015 (%): 2015: World Health Organization; 2016 [updated 2016. Available from: http://gamapserver.who.int/gho/interactive_charts/immunization/mcv/atlas.html.

82. Wang L, Tang Q, Liang G. Rabies and rabies virus in wildlife in mainland China, 1990-2013. Int J Infect Dis. 2014;25:122-9.

83. Leung AK, Davies HD, Hon KL. Rabies: epidemiology, pathogenesis, and prophylaxis. Adv Ther. 2007;24(6):1340-7.

84. Ward MP. Rabies in the Dutch East Indies a century ago - a spatio-temporal case study in disease emergence. Prev Vet Med. 2014;114(1):11-20.

85. Waltner-Toews D, Maryono A, Akoso BT, Wisynu S, Unruh DHA. An epidemic of canine rabies in central Java, Indonesia. Preventive Veterinary Medicine. 1990;8(4):295-303.

86. Susilawathi NM, Darwinata AE, Dwija IB, Budayanti NS, Wirasandhi GA, Subrata K, et al. Epidemiological and clinical features of human rabies cases in Bali 2008-2010. BMC Infect Dis. 2012;12:81.

87. Gautret P, Lim PL, Shaw M, Leder K. Rabies post-exposure prophylaxis in travellers returning from Bali, Indonesia, November 2008 to March 2010. Clin Microbiol Infect. 2011;17(3):445-7.

88. Dibia IN, Sumiarto B, Susetya H, Putra AA, Scott-Orr H, Mahardika GN. Phylogeography of the current rabies viruses in Indonesia. J Vet Sci. 2015;16(4):459-66.

89. Mustiana A, Toribio JA, Abdurrahman M, Suadnya IW, Hernandez-Jover M, Putra AA, et al. Owned and unowned dog population estimation, dog management and dog bites to inform rabies prevention and response on Lombok Island, Indonesia. PLoS One. 2015;10(5):e0124092.

90. Widyastuti MD, Bardosh KL, Sunandar, Basri C, Basuno E, Jatikusumah A, et al. On dogs, people, and a rabies epidemic: results from a sociocultural study in Bali, Indonesia. Infect Dis Poverty. 2015;4:30.

91. Putra AA, Hampson K, Girardi J, Hiby E, Knobel D, Mardiana IW, et al. Response to a rabies epidemic, Bali, Indonesia, 2008-2011. Emerg Infect Dis. 2013;19(4):648-51.

92. Bi Z, Formenty PB, Roth CE. Hantavirus infection: a review and global update. J Infect Dev Ctries. 2008;2(1):3-23.

93. Watson DC, Sargianou M, Papa A, Chra P, Starakis I, Panos G. Epidemiology of Hantavirus infections in humans: a comprehensive, global overview. Crit Rev Microbiol. 2014;40(3):261-72.

94. Goeijenbier M, Wagenaar J, Goris M, Martina B, Henttonen H, Vaheri A, et al. Rodent-borne hemorrhagic fevers: under-recognized, widely spread and preventable - epidemiology, diagnostics and treatment. Crit Rev Microbiol. 2013;39(1):26-42.

95. Moreli ML, Marques-Silva AC, Pimentel VA, da Costa VG. Effectiveness of the ribavirin in treatment of hantavirus infections in the Americas and Eurasia: a meta-analysis. Virusdisease. 2014;25(3):385-9.

96. Goeijenbier M, Hartskeerl RA, Reimerink J, Verner-Carlsson J, Wagenaar JF, Goris MG, et al. The hanta hunting study: underdiagnosis of Puumala hantavirus infections in symptomatic non-travelling leptospirosis-suspected patients in the Netherlands, in 2010 and April to November 2011. Euro Surveill. 2014;19(32).

97.   Ibrahim IN, Sudomo M, Morita C, Uemura S, Muramatsu Y, Ueno H, et al. Seroepidemiological survey of wild rats for Seoul virus in Indonesia. Jpn J Med Sci Biol. 1996;49(2):69-74.

98.   Plyusnina A, Ibrahim IN, Winoto I, Porter KR, Gotama IB, Lundkvist A, et al. Identification of Seoul hantavirus in Rattus norvegicus in Indonesia. Scand J Infect Dis. 2004;36(5):356-9.

99.   Plyusnina A, Ibrahim IN, Plyusnin A. A newly recognized hantavirus in the Asian house rat (Rattus tanezumi) in Indonesia. J Gen Virol. 2009;90(Pt 1):205-9.

100. Kosasih H, Ibrahim IN, Wicaksana R, Alisjahbana B, Hoo Y, Yo IH, et al. Evidence of human hantavirus infection and zoonotic investigation of hantavirus prevalence in rodents in western Java, Indonesia. Vector Borne Zoonotic Dis. 2011;11(6):709-13.

101. Ibrahim IN, Shimizu K, Yoshimatsu K, Yunianto A, Salwati E, Yasuda SP, et al. Epidemiology of hantavirus infection in Thousand Islands regency of Jakarta, Indonesia. J Vet Med Sci. 2013;75(8):1003-8.

102. Groen J, Suharti C, Koraka P, van Gorp EC, Sutaryo J, Lundkvist A, et al. Serological evidence of human hantavirus infections in Indonesia. Infection. 2002;30(5):326-7.

103. Suharti C, van Gorp EC, Dolmans WM, Groen J, Hadisaputro S, Djokomoeljanto RJ, et al. Hanta virus infection during dengue virus infection outbreak in Indonesia. Acta Med Indones. 2009;41(2):75-80.

104. WHO. Human cases of influenza at the human-animal interface, January 2014-April 2015. Wkly Epidemiol Rec. 2015;90(28):349-62.

105. Sedyaningsih ER, Isfandari S, Soendoro T, Supari SF. Towards mutual trust, transparency and equity in virus sharing mechanism: the avian influenza case of Indonesia. Ann Acad Med Singapore. 2008;37(6):482-8.

106. Kandun IN, Tresnaningsih E, Purba WH, Lee V, Samaan G, Harun S, et al. Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet. 2008;372(9640):744-9.

107. Yang Y, Halloran ME, Sugimoto JD, Longini IM, Jr. Detecting human-to-human transmission of avian influenza A (H5N1). Emerg Infect Dis. 2007;13(9):1348-53.

108. Aditama TY, Samaan G, Kusriastuti R, Purba WH, Misriyah, Santoso H, et al. Risk factors for cluster outbreaks of avian influenza A H5N1 infection, Indonesia. Clin Infect Dis. 2011;53(12):1237-44.

109. Aditama TY, Samaan G, Kusriastuti R, Sampurno OD, Purba W, Misriyah, et al. Avian influenza H5N1 transmission in households, Indonesia. PLoS One. 2012;7(1):e29971.

110. Herfst S, Schrauwen EJ, Linster M, Chutinimitkul S, de Wit E, Munster VJ, et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science. 2012;336(6088):1534-41.

111. Mariner JC, Jones BA, Hendrickx S, El Masry I, Jobre Y, Jost CC. Experiences in participatory surveillance and community-based reporting systems for H5N1 highly pathogenic avian influenza: a case study approach. Ecohealth. 2014;11(1):22-35.

112. Azhar M, Lubis AS, Siregar ES, Alders RG, Brum E, McGrane J, et al. Participatory disease surveillance and response in Indonesia: strengthening veterinary services and empowering communities to prevent and control highly pathogenic avian influenza. Avian Dis. 2010;54(1 Suppl):749-53.

113. Barzaga BN. Hepatitis A shifting epidemiology in South-East Asia and China. Vaccine. 2000;18 Suppl 1:S61-4.

114. Vranckx R, Alisjahbana A, Devillé W, Meheus A. Hepatitis A antibodies in Indonesian neonates and children. International Journal of Infectious Diseases. 1997;2(1):31-3.

115. Kunasol P, Cooksley G, Chan VF, Isahak I, John J, Loleka S, et al. Hepatitis A virus: declining seroprevalence in children and adolescents in Southeast Asia. Southeast Asian J Trop Med Public Health. 1998;29(2):255-62.

116. Suwantika AA, Beutels P, Postma MJ. Cost-effectiveness of hepatitis A vaccination in Indonesia. Hum Vaccin Immunother. 2014;10(8):2342-9.

117. Utsumi T, Yano Y, Amin M, Lusida MI, Soetjipto, Hotta H, et al. Acute hepatitis due to hepatitis A virus subgenotype IA as an imported infectious disease from Indonesia. Kobe J Med Sci. 2014;60(2):E43-7.

118. Boggild AK, Castelli F, Gautret P, Torresi J, von Sonnenburg F, Barnett ED, et al. Vaccine preventable diseases in returned international travelers: results from the GeoSentinel Surveillance Network. Vaccine. 2010;28(46):7389-95.

119. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet. 2003;362(9397):1733-45.

120. Storms AD, Kusriastuti R, Misriyah S, Praptiningsih CY, Amalya M, Lafond KE, et al. The East Jakarta Project: surveillance for highly pathogenic avian influenza A(H5N1) and seasonal influenza viruses in patients seeking care for respiratory disease, Jakarta, Indonesia, October 2011-September 2012. Epidemiol Infect. 2015;143(16):3394-404.

121. Kosasih H, Bratasena A, Pangesti K, Laras K, Samaan G. Managing seasonal influenza: oseltamivir treatment policy in indonesia? Acta Med Indones. 2014;46(1):58-65.

122. Ampofo WK, Azziz-Baumgartner E, Bashir U, Cox NJ, Fasce R, Giovanni M, et al. Strengthening the influenza vaccine virus selection and development process: Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014. Vaccine. 2015;33(36):4368-82.

123. Boggild AK, Castelli F, Gautret P, Torresi J, von Sonnenburg F, Barnett ED, et al. Latitudinal patterns of travel among returned travelers with influenza: results from the GeoSentinel Surveillance Network, 1997-2007. J Travel Med. 2012;19(1):4-8.

124. Goeijenbier M, van Genderen P, Ward BJ, Wilder-Smith A, Steffen R, Osterhaus AD. Travellers and influenza: risks and prevention. J Travel Med. 2017;24(1).

125. Wertheim HF, Nadjm B, Thomas S, Agustiningsih A, Malik S, Diep NN, et al. Viral and atypical bacterial aetiologies of infection in hospitalised patients admitted with clinical suspicion of influenza in Thailand, Vietnam and Indonesia. Influenza Other Respir Viruses. 2015.

126. Kwong JC, Druce JD, Leder K. Zika virus infection acquired during brief travel to Indonesia. Am J Trop Med Hyg. 2013;89(3):516-7.

127. Leung GH, Baird RW, Druce J, Anstey NM. Zika Virus Infection in Australia Following a Monkey Bite in Indonesia. Southeast Asian J Trop Med Public Health. 2015;46(3):460-4.

128. Tappe D, Nachtigall S, Kapaun A, Schnitzler P, Gunther S, Schmidt-Chanasit J. Acute Zika virus infection after travel to Malaysian Borneo, September 2014. Emerg Infect Dis. 2015;21(5):911-3.

129. Olson JG, Ksiazek TG, Suhandiman, Triwibowo. Zika virus, a cause of fever in Central Java, Indonesia. Trans R Soc Trop Med Hyg. 1981;75(3):389-93.

130. Perkasa A, Yudhaputri F, Haryanto S, Hayati RF, Ma'roef CN, Antonjaya U, et al. Isolation of Zika Virus from Febrile Patient, Indonesia. Emerg Infect Dis. 2016;22(5):924-5.

131. Corwin A, Putri MP, Winarno J, Lubis I, Suparmanto S, Sumardiati A, et al. Epidemic and sporadic hepatitis E virus transmission in West Kalimantan (Borneo), Indonesia. Am J Trop Med Hyg. 1997;57(1):62-5.

132. Sedyaningsih-Mamahit ER, Larasati RP, Laras K, Sidemen A, Sukri N, Sabaruddin N, et al. First documented outbreak of hepatitis E virus transmission in Java, Indonesia. Trans R Soc Trop Med Hyg. 2002;96(4):398-404.

133. Corwin A, Jarot K, Lubis I, Nasution K, Suparmawo S, Sumardiati A, et al. Two years' investigation of epidemic hepatitis E virus transmission in West Kalimantan (Borneo), Indonesia. Trans R Soc Trop Med Hyg. 1995;89(3):262-5.

134. Widasari DI, Yano Y, Utsumi T, Heriyanto DS, Anggorowati N, Rinonce HT, et al. Hepatitis E Virus Infection in Two Different Community Settings with Identification of Swine HEV Genotype 3 in Indonesia. Microbiol Immunol. 2013.

135. Utsumi T, Hayashi Y, Lusida MI, Amin M, Soetjipto, Hendra A, et al. Prevalence of hepatitis E virus among swine and humans in two different ethnic communities in Indonesia. Arch Virol. 2011;156(4):689-93.
136. Mulyanto KC, Depamede SN, Sriasih M, Takahashi M, Nagashima S, Jirintai S, et al. Frequent detection and characterization of hepatitis E virus variants in wild rats (Rattus rattus) in Indonesia. Arch Virol. 2013;158(1):87-96.
137. Widagdo W, Okba NMA, Stalin Raj V, Haagmans BL. MERS-coronavirus: From discovery to intervention. One Health. 2017;3:11-6.